The release of data abstracts ahead of the American Society of Clinical Oncology congress always create early winners and losers among those presenting, and for small-to-medium sized companies the share price responses can be extreme.
After this year’s abstracts went live on 26 May, some of the biggest share price decliners were Mirati Therapeutics (down by 73% as of 30 May) and SpringWorks Therapeutics (-40%) as investors took a dim view of data from each of their lead oncology candidates
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?